Short Interest in Check-Cap Ltd. (NASDAQ:CHEK) Drops By 14.6%

Check-Cap Ltd. (NASDAQ:CHEK) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 56,000 shares, a drop of 14.6% from the August 31st total of 65,600 shares. Based on an average daily trading volume, of 10,900 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.3% of the company’s shares are short sold.

Check-Cap Stock Down 13.0 %

Check-Cap stock traded down $0.18 during mid-day trading on Friday, hitting $1.17. 59,468 shares of the company’s stock were exchanged, compared to its average volume of 96,044. The firm has a market capitalization of $6.87 million, a P/E ratio of -0.39 and a beta of 0.39. Check-Cap has a fifty-two week low of $1.13 and a fifty-two week high of $4.59. The company’s 50 day simple moving average is $1.85 and its 200-day simple moving average is $2.09.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Check-Cap in a research note on Sunday, September 22nd. They set a “sell” rating on the stock.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.